Sells medical products and therapies, connected-care equipment, and pharmaceuticals to hospitals and other care providers, and to patients at home under physician supervision.
10-K for FY2025, filed Feb 12, 2026
Hospitals, healthcare distributors and government agencies pay for healthcare products, usually when products are delivered. Baxter also earns money over time from equipment leases, connected-care projects and contract manufacturing services.
10-K for FY2025, filed Feb 12, 2026
10-K for FY2025, filed Feb 12, 2026
FY2025 revenue by reportable segment ↗$11.2B
10-K for FY2025, filed Feb 12, 2026
$11.2B ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Medical Products & Therapies
Sold outright
10-K for FY2025, filed Feb 12, 2026 |
47%
FY2022: 48%
|
Medical Products & Therapies, FY2025
$5.3B Sources
|
Sold outright |
|
Healthcare Systems & Technologies
Sold outright
10-K for FY2025, filed Feb 12, 2026 |
27%
FY2022: 29%
|
Healthcare Systems & Technologies, FY2025
$3.1B Sources
|
Sold outright |
|
Pharmaceuticals
Sold outright
10-K for FY2025, filed Feb 12, 2026 |
22%
FY2022: 21%
|
Pharmaceuticals, FY2025
$2.5B Sources
|
Sold outright |
Hospitals, healthcare distributors and government agencies buy healthcare products. Baxter sells through its own sales force and also through independent distributors, drug wholesalers acting as sales agents, and specialty pharmacies or other alternate-site providers.
10-K for FY2025, filed Feb 12, 2026
Not on paper. It lost $957M in FY2025, but brought in more cash than it spent: $332M of free cash flow.
10-Q for Q3 FY2026, filed Oct 29, 2026
$294MView ↗
10-Q for Q3 FY2026, filed Oct 29, 2026
Open tableView ↗
8-K, filed Aug 19, 2026
On August 18, 2026, Baxter International Inc. (the “Company”) appointed John Rogers as Executive Vice President and Chief Financial Officer…View ↗
8-K, filed Jul 30, 2026
The company raised its full-year financial outlook:View ↗
Flat. Revenue was $11.2B in FY2025, about the same as the $12.1B of FY2021.
Exited businesses
Baxter's earlier portfolio included dialysis therapies and BioPharma Solutions contract manufacturing. It sold Kidney Care and BioPharma Solutions, removing those businesses from its portfolio.
10-K for FY2022, filed Feb 9, 2023 10-K for FY2025, filed Feb 12, 2026
Loading...